FOSTER CITY, CA -- (MARKET WIRE) -- December 13, 2006 -- Entelos, Inc. (LSE: ENTL), a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development and product testing, today announces that it has completed the development with Unilever of a large-scale computer model that simulates the induction of skin sensitization. This new, in silico (computer-based) model structures data in a way that enables identification of the key factors associated with the development of skin sensitization and could potentially guide the future development of new models to aid in the safety assessment of consumer products. Entelos has delivered the platform on a non-exclusive basis to Unilever for continued research. Entelos retains full rights to use the technology independently, including rights for all pharmaceutical applications.
